

Mark C Petrie

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5427003/mark-c-petrie-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154
papers

9,604
citations

43
h-index

96
g-index

180
ext. papers

13,333
ext. citations

10.6
avg, IF

5.76
L-index

#	Paper	IF	Citations
154	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1995-2008	59.2	2021
153	Coronary-artery bypass surgery in patients with left ventricular dysfunction. <i>New England Journal of Medicine</i> , 2011 , 364, 1607-16	59.2	759
152	Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2010 , 12, 747-76	12.3	569
151	Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2016 , 374, 1511-20	59.2	444
150	Randomised controlled trial of specialist nurse intervention in heart failure. <i>BMJ: British Medical Journal</i> , 2001 , 323, 715-8		382
149	Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. <i>European Journal of Heart Failure</i> , 2009 , 11, 130-9	12.3	324
148	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 853-872	12.3	264
147	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 377, 41-51	59.2	232
146	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 376, 1956-1964	59.2	185
145	A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. <i>Lancet, The</i> , 2016 , 387, 1298-304	40	166
144	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1353-1368	27.4	155
143	A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2088-2098	15.1	146
142	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019 , 21, 665-675	12.3	145
141	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. <i>Circulation</i> , 2018 , 137, 364-375	16.7	140
140	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. <i>Circulation</i> , 2020 , 141, 90-99	16.7	130
139	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. <i>European Journal of Heart Failure</i> , 2017 , 19, 1131-1141	12.3	114
138	Myocardial Hemorrhage After Acute Reperfused ST-Segment-Elevation Myocardial Infarction: Relation to Microvascular Obstruction and Prognostic Significance. <i>Circulation: Cardiovascular Imaging</i> , 2016 , 9, e004148	3.9	111

137	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019 , 21, 827-843	12.3	107
136	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2016 , 18, 1096-105	12.3	104
135	Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2127-38	15.1	104
134	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). <i>Circulation</i> , 2017 , 135, 724-735	16.7	100
133	Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients With an Acute ST-Segment-Elevation Myocardial Infarction. <i>Circulation</i> , 2016 , 134, 1833-1847	16.7	89
132	Pathophysiology of LV Remodeling in Survivors of STEMI: Inflammation, Remote Myocardium, and Prognosis. <i>JACC: Cardiovascular Imaging</i> , 2015 , 8, 779-89	8.4	85
131	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 196-213	12.3	85
130	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021 , 143, 516-525	16.7	85
129	Effects of urotensin II in human arteries and veins of varying caliber. <i>Circulation</i> , 2001 , 103, 1378-81	16.7	83
128	Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. <i>European Heart Journal</i> , 2016 , 37, 1044-59	9.5	81
127	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020 , 41, 2379-2392	9.5	80
126	EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. <i>European Journal of Heart Failure</i> , 2014 , 16, 583-91	12.3	80
125	Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). <i>Circulation</i> , 2016 , 134, 1314-1324	16.7	79
124	One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	78
123	Temporal Evolution of Myocardial Hemorrhage and Edema in Patients After Acute ST-Segment Elevation Myocardial Infarction: Pathophysiological Insights and Clinical Implications. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	72
122	Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials. <i>JACC: Clinical Electrophysiology</i> , 2015 , 1, 200-209	4.6	69
121	Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. <i>European Journal of Heart Failure</i> , 2010 , 12, 17-24	12.3	65
120	Novel Diabetes Drugs and the Cardiovascular Specialist. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2646-2656	15.1	64

119	Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2018 , 20, 951-962	12.3	62
118	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1845-54	15.1	62
117	Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2017 , 19, 1723-1728	12.3	59
116	Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 697-703	18.1	57
115	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1495-1503	12.3	56
114	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). <i>European Heart Journal</i> , 2014 , 35, 2714-21	9.5	50
113	Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity: The VERIFY 2 Study (A Comparative Study of Resting Coronary Pressure Gradient, Instantaneous Wave-Free Ratio and Fractional Flow Reserve in an Unselected Population Referred for Invasive Angiography). <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	47
112	Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 1984-1986	12.3	44
111	The Emerging Potential of the Apelin-APJ System in Heart Failure. <i>Journal of Cardiac Failure</i> , 2015 , 21, 489-98	3.3	42
110	The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. <i>European Journal of Heart Failure</i> , 2016 , 18, 1491-1498	12.3	41
109	How robust are clinical trials in heart failure?. <i>European Heart Journal</i> , 2017 , 38, 338-345	9.5	37
108	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. <i>European Journal of Heart Failure</i> , 2015 , 17, 1182-91	12.3	37
107	Remote Zone Extracellular Volume and Left Ventricular Remodeling in Survivors of ST-Elevation Myocardial Infarction. <i>Hypertension</i> , 2016 , 68, 385-91	8.5	37
106	Diabetic cardiomyopathy. <i>Heart</i> , 2019 , 105, 337-345	5.1	37
105	Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial: Percutaneous Coronary Intervention for Ischemic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2018 , 6, 517-526	7.9	37
104	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020 , 41, 3787-3797	9.5	35
103	Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. <i>Heart</i> , 2018 , 104, 1995-2002	5.1	34
102	Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2092-2100	15.1	31

101	Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. <i>JCI Insight</i> , 2016 , 1, e85768	9.9	31
100	Return to the Workforce After First Hospitalization for Heart Failure: A Danish Nationwide Cohort Study. <i>Circulation</i> , 2016 , 134, 999-1009	16.7	29
99	Association is not causation: treatment effects cannot be estimated from observational data in heart failure. <i>European Heart Journal</i> , 2018 , 39, 3417-3438	9.5	29
98	Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. <i>JACC: Heart Failure</i> , 2015 , 3, 603-14	7.9	26
97	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021 , 6, 1130-1143	16.2	26
96	Persistent Iron Within the Infarct Core After ST-Segment Elevation Myocardial Infarction: Implications for Left Ventricular Remodeling and Health Outcomes. <i>JACC: Cardiovascular Imaging</i> , 2018 , 11, 1248-1256	8.4	26
95	Tissue sodium excess is not hypertonic and reflects extracellular volume expansion. <i>Nature Communications</i> , 2020 , 11, 4222	17.4	25
94	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 321-332	7.9	22
93	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021 , 42, 3727-3738	9.5	22
92	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. <i>European Journal of Heart Failure</i> , 2016 , 18, 1162-71	12.3	21
91	Angiotensin Receptor-Nepriylsin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021 , 385, 1845-1855	59.2	21
90	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. <i>European Journal of Heart Failure</i> , 2019 , 21, 386-388	12.3	21
89	Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights. <i>JACC: Cardiovascular Imaging</i> , 2019 , 12, 993-1003	8.4	20
88	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 506-522	9.4	20
87	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from COVID-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	20
86	Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. <i>European Journal of Heart Failure</i> , 2020 , 22, 1777-1785	12.3	19
85	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. <i>International Journal of Cardiology</i> , 2016 , 209, 310-6	3.2	19
84	Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. <i>European Journal of Heart Failure</i> , 2012 , 14, 377-86	12.3	18

83	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018 , 11, e004540	7.6	18
82	Assessment of Fractional Flow Reserve in Patients With Recent Non-ST-Segment-Elevation Myocardial Infarction: Comparative Study With 3-T Stress Perfusion Cardiac Magnetic Resonance Imaging. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002207	6	17
81	Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. <i>International Journal of Cardiology</i> , 2016 , 202, 305-10	3.2	17
80	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1472-1477	3.8	17
79	Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. <i>European Journal of Heart Failure</i> , 2015 , 17, 725-34	12.3	17
78	Circumferential Strain Predicts Major Adverse Cardiovascular Events Following an Acute ST-Segment-Elevation Myocardial Infarction. <i>Radiology</i> , 2019 , 290, 329-337	20.5	17
77	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. <i>Circulation: Heart Failure</i> , 2015 , 8, 717-24	7.6	15
76	Altered diaphragm position and function in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2001 , 3, 183-7	12.3	15
75	Ferumoxitol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016 , 18, 46	6.9	15
74	Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. <i>JACC: Heart Failure</i> , 2015 , 3, 618-25	7.9	14
73	Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction. <i>Hypertension</i> , 2018 , 72, 720-730	8.5	14
72	Effect of Nephilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021 , 144, 199-209	16.7	14
71	Comparative Significance of Invasive Measures of Microvascular Injury in Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008505	6	13
70	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021 , 143, 1962-1972	16.7	13
69	Cardiotoxic effects of angiogenesis inhibitors. <i>Clinical Science</i> , 2021 , 135, 71-100	6.5	13
68	Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. <i>European Journal of Heart Failure</i> , 2013 , 15, 1253-61	12.3	12
67	Effects of resistive breathing on exercise capacity and diaphragm function in patients with ischaemic heart disease. <i>European Journal of Heart Failure</i> , 1999 , 1, 297-300	12.3	12
66	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. <i>Lancet, The</i> , 2022 ,	40	12

65	Sex differences in procedural and clinical outcomes following rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 95, 232-241	2.7	12
64	Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization. <i>Circulation: Heart Failure</i> , 2018 , 11, e005531	7.6	12
63	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007830	6	11
62	Predictors of segmental myocardial functional recovery in patients after an acute ST-Elevation myocardial infarction. <i>European Journal of Radiology</i> , 2019 , 112, 121-129	4.7	10
61	Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2014 , 35, 3426-33	9.5	10
60	Persistence of Infarct Zone T2 Hyperintensity at 6 Months After Acute ST-Segment-Elevation Myocardial Infarction: Incidence, Pathophysiology, and Prognostic Implications. <i>Circulation: Cardiovascular Imaging</i> , 2017 , 10,	3.9	10
59	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. <i>Cost Effectiveness and Resource Allocation</i> , 2015 , 13, 19	2.4	10
58	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021 , 23, 527-540	12.3	10
57	High sodium intake, glomerular hyperfiltration, and protein catabolism in patients with essential hypertension. <i>Cardiovascular Research</i> , 2021 , 117, 1372-1381	9.9	9
56	Treatment strategies in ischaemic left ventricular dysfunction: a network meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2020 ,	3	9
55	Peripartum cardiomyopathy: diagnosis and management. <i>Heart</i> , 2018 , 104, 779-786	5.1	9
54	Much Ado about Natrium: modelling tissue sodium as a highly sensitive marker of subclinical and localized oedema. <i>Clinical Science</i> , 2018 , 132, 2609-2613	6.5	9
53	Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure. <i>Hypertension</i> , 2001 , 38, 412-6	8.5	8
52	Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy: results from the ESC EORP PPCM registry. <i>ESC Heart Failure</i> , 2021 , 8, 879-889	3.7	8
51	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 296-301	6.4	7
50	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). <i>Open Heart</i> , 2016 , 3, e000371	3	7
49	Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. <i>Clinical Science</i> , 2001 , 101, 45-51	6.5	7
48	Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 165-8	3.8	7

47	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure: A Systematic Review. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	7
46	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.. <i>Circulation</i> , 2022 ,	16.7	7
45	Cardiotoxicity and myocardial hypoperfusion associated with anti-vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer. <i>European Journal of Heart Failure</i> , 2020 , 22, 1276-1277	12.3	6
44	Who needs an implantable cardioverter-defibrillator? Controversies and opportunities after DANISH. <i>European Journal of Heart Failure</i> , 2018 , 20, 413-416	12.3	6
43	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	6
42	Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. <i>Cardiovascular Research</i> , 2020 , 116, e152-e155	9.9	6
41	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. <i>ESC Heart Failure</i> , 2021 , 8, 129-138	3.7	6
40	Sex-based associations with microvascular injury and outcomes after ST-segment elevation myocardial infarction. <i>Open Heart</i> , 2019 , 6, e000979	3	5
39	Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. <i>European Journal of Heart Failure</i> , 2019 , 21, 699-702	12.3	5
38	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2021 ,	16.7	5
37	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	5
36	Redefining Adverse and Reverse Left Ventricular Remodeling by Cardiovascular Magnetic Resonance Following ST-Segment-Elevation Myocardial Infarction and Their Implications on Long-Term Prognosis. <i>Circulation: Cardiovascular Imaging</i> , 2020 , 13, e009937	3.9	5
35	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. <i>Clinical Epidemiology</i> , 2018 , 10, 917-930	5.9	4
34	Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. <i>Heart</i> , 2020 , 106, 758-764	5.1	4
33	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 2058-2068	15.1	4
32	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e019238	6	3
31	Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	3
30	Mechanical circulatory support for refractory cardiogenic shock post-acute myocardial infarction-a decade of lessons. <i>Journal of Thoracic Disease</i> , 2019 , 11, 542-548	2.6	2

29	Ventricular assist devices as rescue therapy in cardiogenic shock after subarachnoid hemorrhage. <i>Annals of Thoracic Surgery</i> , 2014 , 97, 1440-3	2.7	2
28	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008837	7.6	2
27	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1298-1305	16.2	2
26	Type 1 diabetes mellitus and coronary revascularization. <i>Cardiovascular Endocrinology and Metabolism</i> , 2019 , 8, 35-38	2.5	2
25	Prevalence and profile of "seasonal frequent flyers" with chronic heart disease: Analysis of 1598 patients and 4588 patient-years follow-up. <i>International Journal of Cardiology</i> , 2019 , 279, 126-132	3.2	2
24	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. <i>Heart</i> , 2021 ,	5.1	2
23	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. <i>Cardiovascular Research</i> , 2021 ,	9.9	2
22	Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". <i>Circulation</i> , 2021 , 144, e40	16.7	2
21	Reflections on the Danish Revolution. <i>European Heart Journal</i> , 2004 , 25, 540-2	9.5	1
20	Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. <i>Open Heart</i> , 2018 , 5, e000752	3	1
19	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. <i>Open Heart</i> , 2021 , 8,	3	1
18	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. <i>Open Heart</i> , 2021 , 8, e001453	3	1
17	Ferumoxitol-enhanced MRI in patients with prior cardiac transplantation. <i>Open Heart</i> , 2019 , 6, e001115	3	1
16	Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.. <i>Kidney360</i> , 2021 , 2, 1761-1769	1.8	1
15	Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: State-of-the-Art Review.. <i>JACC: CardioOncology</i> , 2022 , 4, 1-18	3.8	1
14	PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes 2022 , 1, 100020		1
13	A Noncontrast CMR Risk Score for Long-Term Risk Stratification in Reperfused ST-Segment Elevation Myocardial Infarction.. <i>JACC: Cardiovascular Imaging</i> , 2022 , 15, 431-440	8.4	0
12	Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. <i>PLoS ONE</i> , 2021 , 16, e0255364	3.7	0

11	Response to the letter regarding the hypothesis paper "Much ado about Natrium: modelling tissue sodium as a highly sensitive marker of subclinical and localised oedema". <i>Clinical Science</i> , 2019 , 133, 761	6.5
10	115 Persistence of Infarct Zone Oedema at 6 Months after Acute ST-elevation Myocardial Infarction: Incidence, Pathophysiology and Association with Left Ventricular Remodelling. <i>Heart</i> , 2016 , 102, A81.2-A81	5.1
9	114 Persistence of Haemoglobin Degradation Products within Infarct Scar Tissue after ST-elevation Myocardial Infarction: Incidence, Correlates and Implications for Left Ventricular Remodelling. <i>Heart</i> , 2016 , 102, A81.1-A81	5.1
8	2 Coronary flow reserve and index of microvascular resistance in acute stemi. <i>Heart</i> , 2016 , 102, A1.2-A1	5.1
7	109 Left Ventricular Outcomes Following Multivessel PCI Vs. Infarct-Only PCI in Patients with Acute Stemi: The Glasgow Prami CMR Sub-Study. <i>Heart</i> , 2015 , 101, A62.2-A62	5.1
6	110 Infarct Burden Following Multivessel PCI Vs. Infarct-Only PCI in Patients with Acute Stemi: The Glasgow Prami CMR Sub-Study. <i>Heart</i> , 2015 , 101, A63.1-A63	5.1
5	Feasibility/eligibility of T-wave alternans testing in patients with heart failure: should we rethink our current modus operandi?: reply. <i>European Journal of Heart Failure</i> , 2012 , 14, 676-677	12.3
4	Microvolt T-wave alternans testing should be used to guide arrhythmic therapy in heart failure patients: reply. <i>European Journal of Heart Failure</i> , 2012 , 14, 678-678	12.3
3	Diabetes, Left Ventricular Systolic Dysfunction and Chronic Heart Failure 93-134	
2	I'm sorry Mr Paxman!. <i>Scottish Medical Journal</i> , 2005 , 50, 149-50	1.8
1	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020 , 7, 1-86	1.7